Pfizer has partnered with molecular information firm Foundation Medicine to develop and commercialise companion diagnostics (CDx) for its oncology portfolio.
The new diagnostics will be added as updates to FoundationOne CDx, which is a comprehensive genomic profiling (CGP) assay comprising various companion diagnostics.
FoundationOne is said to analyse all types of genomic alterations in 324 genes that are known to be associated with cancer growth, as well as genomic biomarkers that could predict the use of immunotherapies.
It is approved by the US Food and Drug Administration (FDA) for all solid tumours and as a broad companion diagnostic for certain types of non-small cell lung, melanoma, colorectal, ovarian, and breast cancers to identify patients who can benefit from using one of 17 on-label targeted therapies.
Under the collaboration, Pfizer will also have access to Foundation Medicine’s data analytics platform called FoundationInsights designed to enable discovery of new biomarkers and optimise clinical trial design.
FoundationOne and FoundationInsights are expected to allow Pfizer to use Foundation Medicine’s platform technology to advance discovery and development of precision oncology therapies.
Foundation Medicine biopharma chief business officer and head Melanie Nallicheri said: “We are proud to partner with Pfizer who shares our commitment to precision oncology and biomarker-driven drug development.
“The combination of our FDA-approved comprehensive genomic profiling platform and molecular information solutions, coupled with Pfizer’s robust oncology portfolio, enables us to enhance the impact of precision oncology to advance patient care.”
Pfizer’s existing oncology portfolio includes ten FDA-approved medicines for various types of solid tumours and hematologic malignancies.
The firm also has a pipeline of 17 candidates in clinical development and 19 Phase III trials.